Restless Legs: What Could Be Causing It

The Dopamine-Iron Connection at the Center of RLS

Restless legs syndrome is a neurological sensorimotor disorder, not a musculoskeletal one. The urge to move originates in the central nervous system, driven by disrupted dopaminergic signaling in the basal ganglia and spinal cord. Iron serves as an essential cofactor for tyrosine hydroxylase, the rate-limiting enzyme in dopamine synthesis, which is why brain iron deficiency and dopaminergic dysfunction are two sides of the same coin in RLS pathophysiology [1].

Autopsy and MRI studies have consistently shown reduced iron in the substantia nigra of RLS patients compared with age-matched controls, even when peripheral serum iron levels appear normal [2]. A 2020 meta-analysis published in Sleep Medicine Reviews (23 studies, N=2,857) confirmed that cerebrospinal fluid ferritin is significantly lower in RLS patients while transferrin is elevated, indicating the brain is iron-hungry regardless of what a standard blood panel shows [3]. This is why the International Restless Legs Syndrome Study Group (IRLSSG) recommends checking serum ferritin in every patient and treating with oral or intravenous iron when ferritin falls below 75 µg/L, a threshold well above the 12 to 15 µg/L cutoff used to define systemic anemia [4].

The practical takeaway: a "normal" complete blood count does not rule out the most common treatable cause of RLS.

Iron Deficiency: The Single Most Actionable Cause

If you have restless legs, checking your iron status is the first clinical step. Serum ferritin below 75 µg/L is the treatment threshold recommended by the IRLSSG, and oral iron supplementation (325 mg ferrous sulfate every other day with vitamin C on an empty stomach) is the initial approach [4]. Absorption is better with alternate-day dosing than daily dosing, a finding demonstrated in a 2017 randomized trial in The Lancet Haematology (N=54) [5].

For patients who do not respond to oral iron after 12 weeks, or whose ferritin remains below 75 µg/L, intravenous ferric carboxymaltose (1 to 000 mg single infusion) has shown significant RLS symptom improvement. In a double-blind, placebo-controlled trial (N=459), IV iron reduced IRLS severity scores by a mean of 7.7 points versus 3.5 for placebo at 6 weeks [6]. The response can last months.

Who is at risk for iron-deficient RLS? Premenopausal women with heavy menstrual bleeding, frequent blood donors, vegetarians, patients on proton pump inhibitors, and anyone with occult gastrointestinal blood loss. A ferritin check costs less than a copay for a sleep study.

Genetics: More Than 20 Loci and Counting

RLS runs in families. About 50 to 60 percent of patients with primary (idiopathic) RLS report a first-degree relative with the same symptoms [7]. Genome-wide association studies have identified over 20 susceptibility loci, with the strongest signals at MEIS1, BTBD9, and MAP2K5/SKOR1 [8]. The MEIS1 variant alone carries an odds ratio of approximately 2.0 for RLS, making it one of the largest common-variant effect sizes in sleep medicine.

These genetic findings do more than explain heritability. They point to developmental pathways in spinal cord interneurons and iron regulation networks, reinforcing the dopamine-iron model from a completely independent angle [8]. Genetic testing is not clinically indicated for diagnosis, but a strong family history should prompt earlier evaluation and a lower threshold for treatment. Patients with genetic RLS tend to develop symptoms before age 45, have a slower disease progression, and may respond differently to pharmacotherapy compared with late-onset secondary RLS [7].

Medications That Trigger or Worsen Restless Legs

A medication review is mandatory in every RLS evaluation. Several drug classes are well-documented triggers that can cause new-onset RLS or worsen existing symptoms. The most common offenders, as outlined in the 2022 AASM Clinical Practice Guideline [9]:

Antidepressants. SSRIs (sertraline, fluoxetine, citalopram) and SNRIs (venlafaxine, duloxetine) increase serotonin signaling, which may inhibit dopaminergic activity. Mirtazapine is a frequent culprit. Bupropion, which acts on dopamine and norepinephrine, is the preferred alternative when an antidepressant is needed in an RLS patient [9].

Antihistamines. Diphenhydramine (Benadryl), found in most over-the-counter sleep aids, blocks central dopamine receptors in addition to histamine. This is a common and overlooked cause of worsening nighttime RLS.

Dopamine-blocking antiemetics. Metoclopramide and prochlorperazine cross the blood-brain barrier and antagonize D2 receptors. Ondansetron (Zofran) is a safer antiemetic choice for RLS patients.

Lithium. Case reports and small series describe RLS induction with lithium use [10].

Dr. John Winkelman of Massachusetts General Hospital and Harvard Medical School, a leading RLS researcher, has stated: "The single most impactful thing a clinician can do for a patient with worsening RLS is review the medication list. Many patients are inadvertently being given drugs that fight against their RLS treatment" [9].

Stopping or substituting the offending medication may resolve symptoms entirely without adding a new prescription.

Pregnancy and Hormonal Shifts

Restless legs during pregnancy is common enough to be considered a distinct clinical entity. A 2019 meta-analysis in Sleep Medicine Reviews pooled 51 studies (N=59,397) and found a prevalence of 21% overall, peaking at 26% during the third trimester [11]. Symptoms typically resolve within weeks of delivery.

The mechanism is multifactorial. Estrogen and progesterone fluctuations alter dopaminergic tone in the striatum. Iron and folate demands increase dramatically as plasma volume expands by 40 to 50% by the third trimester. And mechanical factors (venous compression, edema) may contribute to peripheral discomfort that compounds the central neurological urge to move.

Iron supplementation is the primary treatment during pregnancy. Pharmacological options are limited by fetal safety concerns. Gabapentin and pregabalin are Category C. Dopamine agonists lack sufficient pregnancy safety data. Low-dose oxycodone has been used in refractory cases, but this requires careful risk-benefit discussion [12].

Women who develop RLS during their first pregnancy have a 30 to 40% chance of recurrence in subsequent pregnancies and an increased lifetime risk of developing chronic RLS [11]. This makes pregnancy-onset RLS a useful prognostic marker.

Chronic Kidney Disease and Dialysis

End-stage renal disease (ESRD) carries the highest RLS prevalence of any medical condition. Studies report rates between 20% and 57% in dialysis patients, compared with the 5 to 15% background rate [13]. The 2023 Kidney International review by Giannaki et al. confirmed that uremic RLS correlates with higher mortality, worse cardiovascular outcomes, and markedly reduced quality of life independent of other uremic symptoms [13].

The pathophysiology in CKD differs partly from primary RLS. Uremic toxins disrupt dopamine metabolism. Iron stores may appear adequate on serum testing, but functional iron deficiency (elevated transferrin saturation with low ferritin) is common. Phosphate-binder use and metabolic acidosis add further variables.

Dr. Christopher Earley of Johns Hopkins University, one of the foremost investigators in RLS neurobiology, noted in a 2021 review: "Renal patients with RLS represent a uniquely challenging population because the usual biomarkers for iron deficiency are unreliable in the context of chronic inflammation and erythropoietin use" [14].

Treatment in dialysis patients centers on IV iron (targeting ferritin above 200 µg/L and transferrin saturation above 20%), gabapentinoids adjusted for renal clearance, and optimizing dialysis adequacy. Dopamine agonists should be used cautiously given the higher augmentation risk in this population [13].

Neuropathy and Other Neurological Overlap

Small fiber neuropathy and RLS share uncomfortable overlap. Between 20 and 36% of patients initially diagnosed with RLS have concurrent small fiber neuropathy on skin biopsy [15]. Whether the neuropathy causes RLS-like symptoms, merely coexists, or shares a common upstream mechanism (such as impaired iron-dependent nerve metabolism) remains debated.

Conditions that should be considered in the differential:

• Peripheral neuropathy (diabetic, alcoholic, chemotherapy-induced): burning, tingling sensations in the legs that worsen at rest. Unlike RLS, the discomfort does not improve with movement.
• Akathisia: inner restlessness without the specific leg-focused urge. Common with antipsychotics.
• Nocturnal leg cramps: involuntary muscle contractions that are painful and focal, distinct from the diffuse creeping discomfort of RLS.
• Peripheral artery disease: claudication at rest in severe cases. Ankle-brachial index testing clarifies.
• Venous insufficiency: heaviness and aching that improves with leg elevation, worsens with prolonged standing. Duplex ultrasound can differentiate.

A 2018 study in Neurology (N=234) found that 36% of patients referred to a tertiary RLS clinic actually had a neuropathic mimic rather than true RLS, underscoring the importance of applying the IRLSSG diagnostic criteria carefully [15].

How RLS Is Diagnosed

RLS is a clinical diagnosis. There is no blood test, imaging study, or polysomnography finding that confirms it. The IRLSSG established five essential diagnostic criteria, updated in 2014 [16]:

1. An urge to move the legs, usually accompanied by uncomfortable sensations.
2. Symptoms begin or worsen during rest or inactivity.
3. Symptoms are partially or totally relieved by movement.
4. Symptoms occur exclusively or predominantly in the evening or at night.
5. The above features are not solely accounted for by another medical or behavioral condition.

All five must be met. Criterion 5 is the most clinically demanding, requiring exclusion of mimics like positional discomfort, habitual foot tapping, and leg cramps.

Recommended laboratory workup includes serum ferritin (target above 75 µg/L), transferrin saturation, complete metabolic panel (to assess renal function), thyroid-stimulating hormone, hemoglobin A1c, and vitamin B12/folate levels [4]. A polysomnography is not required for diagnosis but may be ordered if periodic limb movements of sleep (PLMS) need quantification. About 80 to 90% of RLS patients exhibit PLMS on overnight study, though PLMS alone does not confirm RLS [16].

A sleep study becomes relevant when the clinician suspects concurrent obstructive sleep apnea, which occurs in roughly 10 to 20% of RLS patients and can independently fragment sleep [17].

First-Line Treatment: Beyond Iron

Once iron status is optimized, pharmacotherapy follows a clear hierarchy established by the 2022 AASM Clinical Practice Guideline and reinforced by a 2024 Lancet Neurology expert consensus [9][18].

Alpha-2-delta ligands (gabapentinoids) are now recommended as first-line, displacing dopamine agonists. Gabapentin enacarbil (Horizant), 600 mg taken at 5 PM, demonstrated a mean 4.0-point IRLS score reduction versus placebo in a key trial (N=325) [19]. Pregabalin (150 to 450 mg nightly) showed comparable efficacy in a head-to-head trial against pramipexole, with a lower rate of augmentation at 52 weeks (2% vs. 7.7%) [20].

Dopamine agonists (pramipexole 0.125 to 0.5 mg, ropinirole 0.25 to 4 mg, rotigotine patch 1 to 3 mg) remain second-line. Their major liability is augmentation, a paradoxical worsening of RLS symptoms that occurs in 30 to 70% of patients over 10 years of continuous use [21]. The IRLSSG now recommends using dopamine agonists at the lowest effective dose, avoiding dose escalation, and monitoring for augmentation at every visit.

Low-dose opioids (oxycodone 5 to 15 mg) are reserved for refractory cases. A 2014 randomized trial in The Lancet Neurology (N=306) demonstrated that prolonged-release oxycodone/naloxone produced significant IRLS improvement, but dependency risk limits this to patients who have failed or cannot tolerate first- and second-line agents [22].

Non-pharmacological strategies with evidence include moderate aerobic exercise (three to five sessions per week), pneumatic compression devices (FDA-cleared for RLS), avoidance of evening caffeine and alcohol, and cognitive behavioral therapy for insomnia in patients with comorbid sleep-onset difficulty [9].

When to Seek Urgent Evaluation

Most RLS is manageable in a primary care setting. Certain presentations warrant referral to a sleep medicine specialist or neurologist:

Symptoms that begin suddenly in a patient over 50 with no family history. This pattern suggests secondary RLS and demands a thorough workup for iron malabsorption, renal impairment, or neuropathy. RLS that worsens despite iron repletion and guideline-directed pharmacotherapy needs reevaluation; augmentation, medication-induced RLS, or a misdiagnosed mimic may be driving the picture.

Severe sleep disruption (sleeping fewer than 5 hours per night due to RLS) deserves urgent attention because of its association with increased cardiovascular risk. A 2021 cohort study in Neurology (N=3,700) found that RLS with frequent PLMS was associated with a 36% higher incidence of cardiovascular events over 8 years of follow-up [23].

Any patient with RLS and concurrent depression should be screened for suicidal ideation, as severe chronic insomnia compounds mood disorder risk. Bupropion is the preferred antidepressant in this scenario because of its dopaminergic mechanism [9].

A ferritin level below 30 µg/L with symptomatic RLS should prompt evaluation for gastrointestinal blood loss, including celiac disease screening, especially in patients under 50 without an obvious dietary explanation.